Farther Finance Advisors LLC Purchases 11,546 Shares of Arrowhead Pharmaceuticals, Inc. $ARWR

Farther Finance Advisors LLC grew its position in shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) by 2,923.0% in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 11,941 shares of the biotechnology company’s stock after acquiring an additional 11,546 shares during the quarter. Farther Finance Advisors LLC’s holdings in Arrowhead Pharmaceuticals were worth $793,000 at the end of the most recent reporting period.

Several other hedge funds also recently made changes to their positions in the business. Vanguard Group Inc. lifted its position in shares of Arrowhead Pharmaceuticals by 3.3% in the third quarter. Vanguard Group Inc. now owns 16,035,870 shares of the biotechnology company’s stock worth $553,077,000 after purchasing an additional 510,798 shares in the last quarter. Avoro Capital Advisors LLC grew its position in Arrowhead Pharmaceuticals by 2.8% in the third quarter. Avoro Capital Advisors LLC now owns 10,900,000 shares of the biotechnology company’s stock valued at $375,941,000 after purchasing an additional 300,000 shares in the last quarter. Arrowstreet Capital Limited Partnership increased its stake in Arrowhead Pharmaceuticals by 3,142.5% in the 3rd quarter. Arrowstreet Capital Limited Partnership now owns 2,081,689 shares of the biotechnology company’s stock valued at $71,797,000 after buying an additional 2,017,489 shares during the last quarter. Goldman Sachs Group Inc. lifted its position in Arrowhead Pharmaceuticals by 34.6% during the 1st quarter. Goldman Sachs Group Inc. now owns 1,741,666 shares of the biotechnology company’s stock worth $22,189,000 after buying an additional 447,456 shares in the last quarter. Finally, Baker BROS. Advisors LP lifted its position in Arrowhead Pharmaceuticals by 77.9% during the 3rd quarter. Baker BROS. Advisors LP now owns 1,670,762 shares of the biotechnology company’s stock worth $57,625,000 after buying an additional 731,588 shares in the last quarter. 62.61% of the stock is owned by institutional investors.

Insider Activity

In other news, insider James C. Hamilton sold 10,000 shares of the firm’s stock in a transaction that occurred on Thursday, March 5th. The stock was sold at an average price of $64.19, for a total value of $641,900.00. Following the completion of the sale, the insider directly owned 236,958 shares of the company’s stock, valued at $15,210,334.02. This trade represents a 4.05% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. 3.60% of the stock is currently owned by insiders.

Analyst Ratings Changes

Several brokerages have recently weighed in on ARWR. HC Wainwright restated a “buy” rating and issued a $100.00 price objective on shares of Arrowhead Pharmaceuticals in a report on Wednesday, March 25th. Morgan Stanley upgraded Arrowhead Pharmaceuticals from an “equal weight” rating to an “overweight” rating and upped their target price for the stock from $78.00 to $100.00 in a report on Tuesday. Weiss Ratings raised Arrowhead Pharmaceuticals from a “sell (d-)” rating to a “hold (c-)” rating in a research report on Friday, February 6th. Piper Sandler restated an “overweight” rating and issued a $110.00 price target (up from $100.00) on shares of Arrowhead Pharmaceuticals in a research note on Tuesday, January 13th. Finally, Chardan Capital boosted their price target on Arrowhead Pharmaceuticals from $60.00 to $80.00 and gave the stock a “buy” rating in a research report on Wednesday, January 7th. One analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating and three have given a Hold rating to the stock. According to MarketBeat.com, Arrowhead Pharmaceuticals has a consensus rating of “Moderate Buy” and a consensus price target of $83.78.

Arrowhead Pharmaceuticals Stock Up 0.6%

Arrowhead Pharmaceuticals stock opened at $74.40 on Friday. The company has a debt-to-equity ratio of 0.29, a current ratio of 3.38 and a quick ratio of 3.38. The company’s 50-day moving average is $62.63 and its 200-day moving average is $57.95. The firm has a market capitalization of $10.42 billion, a PE ratio of 48.63 and a beta of 1.26. Arrowhead Pharmaceuticals, Inc. has a fifty-two week low of $12.44 and a fifty-two week high of $76.76.

Arrowhead Pharmaceuticals (NASDAQ:ARWR) last issued its earnings results on Thursday, February 5th. The biotechnology company reported $0.22 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.60 by ($0.38). Arrowhead Pharmaceuticals had a net margin of 18.54% and a return on equity of 35.64%. The firm had revenue of $264.03 million during the quarter, compared to analyst estimates of $225.66 million. During the same quarter last year, the business posted ($1.39) earnings per share. The company’s revenue for the quarter was up 10461.3% on a year-over-year basis. Sell-side analysts anticipate that Arrowhead Pharmaceuticals, Inc. will post -3.37 earnings per share for the current year.

Arrowhead Pharmaceuticals Profile

Arrowhead Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Since its founding in 2008, Arrowhead has leveraged its proprietary delivery platform—known internally as the Advanced RNAi Compound (ARC) technology—to silence disease-causing genes in patients suffering from genetically defined diseases. The company’s approach aims to offer durable, targeted treatments across a range of therapeutic areas.

The company’s pipeline includes multiple candidates in various stages of development.